12.10.2018 • NewsElaine BurridgePKN OrlenUnipetrol

PKN Orlen Takes Control of Unipetrol

PKN Orlen Takes Control of Unipetrol (c) PKN Orlen
PKN Orlen Takes Control of Unipetrol (c) PKN Orlen

Poland’s PKN Orlen has taken 100% ownership of Czech refiner and petrochemicals producer Unipetrol with effect from Oct. 1 following the completion of a squeeze-out of remaining shareholders.

Unipetrol has also been delisted from the Prague Stock Exchange as of Sept. 26.

The squeeze-out was approved by shareholders at a meeting on Aug. 28.  Orlen bought the Czech state’s 63% share in Unipetrol in 2004. It then raised its stake to 94.03% in February following a voluntary tender offer to minority shareholders.

Unipetrol has a naphtha cracker in Litvinov producing 544,000 t/y ethylene as well as downstream plants for PP, PE. It also has a complex in Spolana where it produces PVC, caprolactam, industrial fertilizers and inorganic compounds.

Orlen announced in June its largest petrochemical investment program on record, amounting to $2.3 billion. The company said the investment would enable deeper integration of its refining and petrochemical segments and further diversify its revenue sources.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.